"We have already put a lot of effort into our
support but that has not been enough," Manabu Sakai, senior
executive officer at Daiichi Sankyo, told an earnings briefing on
"We want to go back and prepare a more aggressive, more drastic
Sakai said it was inevitable the incident would affect Daiichi
Sankyo's earnings but was unable to give concrete numbers. The
company is not thinking about reducing its stake in Ranbaxy, he
added, although financial support would be among the actions it will
The U.S. Food and Drug Administration last week banned Ranbaxy's
Toansa plant, a key supplier of ingredients to the generic
drugmaker's U.S. factory, from sending its products to the United
States due to manufacturing violations. It was the fourth Ranbaxy
plant to be shut out of the U.S. market.
"There's been a steady increase in the things that we need to do,"
Sakai said, adding Daiichi Sankyo would dispatch additional
personnel to the plant to help sort out problems.
[to top of second column]
Daiichi Sankyo's shares are down nearly 10 percent
since last week's news on the Toansa plant. On Friday, they rose 2.7
percent to 1,723 yen, bouncing from a five-month low hit the day
(Reporting by Ritsuko Shimizu; editing
by Edmund Klamann and Mark Potter)
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.